| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.24 | 0.4 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |